Fairvalue-Calculator Fairvalue-Calculator
EN DE

InterCure Ltd (INCR) Fair Value & Analysis

Healthcare · US · Market cap $53.1M

Price$1.09
Fair Value$1.44
Upside+32.1%
Quality95/100
Evidence: Medium Range $0.9700 – $2.84

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

InterCure Ltd (INCR) currently trades at $1.09, while our model-based Fair Value estimate is $1.44 — implying the stock looks roughly 32.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is InterCure Ltd (INCR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.44 versus a price of $1.09 — about +32% (undervalued). Model-based estimate, not financial advice.
What is the fair value of INCR?
Our 21-model fair value for InterCure Ltd is $1.44 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.09.
What is the quality score of INCR?
InterCure Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.